Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genzyme’s Lumizyme REMS Eliminated Due To Expanded Indication

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA approves Lumizyme for all Pompe disease patients, making it unnecessary to restrict use to a specific age group; Myozyme, produced at a different scale, will remain available.


Related Content

When To End A REMS? Soliris Review Stirs Debate On How To Scale Back
GSK’s Promacta Adds ‘Breakthrough’ Claim On Strength Of Small NIH Study
FDAAA Fading? REMS Use Continues To Decline As Drug Safety Law Matures
FDA To Sponsors: Say Goodbye To MedGuide-Only REMS
QOL Medical’s Sucraid Is First To Lose Its REMS


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts